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igher risk of developing malignancy. Molecular changes seem suitable for this purpose, but could require a high resource expenditure. While
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rying to identify the best predictive factors for cancer risk, molecular changes and differences in miRNA expression profile between the
arious steps leading to cancer could help to clarify Barrett’s carcinogenesis. In this attempt to find a molecular explanation for the onset of
sophageal adenocarcinoma, it is still difficult to understand whether the molecular changes are causes or effects of the neoplastic phenotypic
odifications.
 2013 Elsevier Ireland Ltd. All rights reserved.
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study showed that the four major risk factors – i.e. obesity,.  Introduction
Barrett’s esophagus (BE) is characterized by the replace-
ent of the normal squamous epithelium by a columnar-lined
pithelium in the distal portion of the esophagus [1,2]. When
he esophagus is chronically exposed to gastric reflux, a pro-
ective response is initiated which leads to metaplasia [3,4].
BE can be diagnosed when a segment of columnar meta-
lasia of any length is found by endoscopic detection above
he esophagogastric junction, but it needs to be confirmed by
istological analysis [5]. This condition is most frequently
ssociated with long-standing gastroesophageal reflux dis-
ase (GERD). Whilst this represents the main precursor
esion for the development of esophageal adenocarcinoma
EA), it can progress through various grades of dyspla-
ia before the development of cancer [6]. However, despite
his relationship between GERD, BE and EA, symptomatic
ERD is infrequent or absent in 40–48% of people who
evelop EA.
The increasing prevalence of esophageal adenocarcinoma
ustifies the increased interest in its precursor lesion, BE. Sev-
ral variations in gene expression show a relationship with
ts progression to cancer. However, the current sequence of
olecular events is as yet unknown, and we lack an explana-
ion for Barrett’s carcinogenesis.
.  The  epidemiology  of  Barrett’s  esophagus  and
sophageal adenocarcinoma
In Western countries GERD affects 10–20% of the pop-
lation. The incidence is approximately 5 per 1000 persons
er year [7]. BE is usually found in middle-aged adults. The
revalence of BE ranges from 0.9% to 4.5% of the general
opulation. The prevalence of endoscopic BE (columnar-
ined epithelium) in reflux-disease patients referred for
ndoscopy usually ranges from 10% to 15% in Western
ountries, and 1.6% of them have histologically confirmed
ntestinal metaplasia [8,9].
The prevalence of EA has been increasing significantly in
estern countries [10,11]. In 2005 there were 497,700 new
ases, and the prevalence is expected to increase worldwide
y approximately 140% by 2025. EA has a poor prognosis,
ith the overall 5-year survival remaining less than 20%;
16,500 people are estimated to have died from esophageal
ancer in 2005 [12]. Whilst worldwide squamous-cell
c
a
6arcinoma is the most common histotype, in many Western
ountries adenocarcinoma has become the most prevalent
orm of esophageal cancer. This phenomenon represents
he most dramatic epidemiological shift ever recorded,
ince esophageal adenocarcinoma has gone from being an
nknown disease until the 1950s to the fastest increasing
ancer in America in the 2000s [13]. New patients will be
iagnosed with esophageal cancer, and more than 50% of
ases will be adenocarcinoma. This increasing incidence
nvolves all disease stages and all ages, but the greatest
ncrease is in men over 65 years old.
A recent English publication concerning the incidence and
urvival of esophageal cancer reported that the incidence of
his malignancy increased until 2002, then remained rela-
ively stable, whereas gastric cancer declined over this period
14].
BE has been considered a strong risk factor for EA with an
ssumed risk of 0.5%, but when only high-quality epidemio-
ogical studies are analyzed the EA incidence in BE is 0.39%
nd even lower, at least in Europe, with an absolute annual
isk of 0.12% [15,16].
Obesity, defined as body mass index (BMI) > 30 kg/m2,
s also a clear risk factor for EA. Two recent meta-
nalyses have estimated relative risks for developing cancer
f between 2.4 and 2.8 for those with a BMI > 30 kg/m2
obese) and between 1.5 and 1.8 for those considered over-
eight (BMI = 25.0–29.9 kg/m2) [17,18].
Some preliminary findings suggest a correlation between
ERD and obesity. For this reason obese people with symp-
omatic GERD had a substantially higher risk for EA (odds
atio [OR] = 16.5, 95% CI = 8.9–30.6) than people with obe-
ity but no reflux (OR = 2.2, 95% CI = 1.1–4.3) or reflux but
o obesity (OR = 5.6, 95% CI = 2.8–11.3) compared to people
ith a healthy BMI and no reflux symptoms [19].
Other weaker risk factors for EA include cigarette smok-
ng, which approximately doubles the risk, and a diet low
n fruits and vegetables. Alcohol does not appear to have an
mportant role in EA. Infection with Helicobacter  pylori  is
elated to a reduced EA risk, even though the mechanism
xplaining this inverse correlation has not yet been clarified.
he reduction in acid reflux that accompanies gastric atrophy
as been proposed as a possible mechanism. A multicenterigarette smoking, chronic GERD, and a diet low in fruits
nd vegetables – collectively were found in 79% (95% CI:
6–87%) of EA cases [20].
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.  The  steps  in  Barrett’s  carcinogenesis
Adenocarcinoma of the esophagus may develop through
 series of morphological stages: from metaplasia to increas-
ng grade of dysplasia and eventually to adenocarcinoma
see Fig. 1 for the metaplasia–dysplasia–adenocarcinoma
equence) [21,22].
At the molecular level, compared to colorectal carcino-
enesis this multistep process has not yet been well-defined
23]. However, Barrett’s carcinogenesis has a similar multi-
tep process consisting of genetic and epigenetic mutations,
hich over many years can lead to increasing genomic insta-
ility and eventually to an autonomous clone of cells with
nvasive and metastatic features. In fact the time course of
he progression to adenocarcinoma is extremely variable.
.1.  Gastric  metaplasia
The interaction between acid reflux and proliferating adult
rogenitor cells of the squamous epithelium results in a
enetic switch that causes a columnar transformation of the
pithelium and the subsequent appearance of cardiac meta-
lasia in the distal esophagus [22]. Columnar metaplasia in
he esophagus without intestinal specialized epithelium is
bsolutely specific for GERD. This marker could be consid-
red the first step of Barrett’s carcinogenesis, but whether
t is a criterion for inclusion in standardized endoscopic
urveillance programs is still a matter for debate [24,25].
he aberrant expression of keratin 7 is an early marker of
he connection between GERD and columnar-lined esopha-
us. The Aurora-A over-expression may be a confirmation of
his relationship [26–28].
.2.  Intestinal  metaplasia
Intestinal metaplasia cannot be considered a marker for
ancer risk since it can be found in most cases of BE,
lthough not all [29]. If esophageal dysplasia and adenocar-
inoma are believed to develop on a background of intestinal
etaplasia, this belief leads to the misconception that with-
ut metaplasia cancer risk may be low [30]. The presence
f a columnar metaplasia of the esophagus implies cancer
isk regardless the intestinal phenotype. Moreover, even in
he absence of detectable goblet cells, Barrett’s mucosa still
xpresses markers and shows ultrastructural features consis-
ent with intestinal differentiation [31,32].
.3.  Dysplasia
Dysplasia can be considered a clear marker of cancer
isk in BE. It implies architectural and cytological changes
ommonly associated with carcinomas. For this reason it
s presumed that carcinoma could evolve from dysplasia.
athologists frequently do not agree on the identification of
ild and moderate (low-grade) dysplasia. However, there is
etter agreement on severe (high-grade) dysplasia (HGD)
w
h
s
egy/Hematology 86 (2013) 278–289
33]. As a focal pattern in dysplasia can often be found,
eliable detection needs several biopsies. This requirement
mplies that the endoscopic surveillance process may be
omplex [34]. We know that dysplasia can progress to higher-
rade forms or invasive adenocarcinoma, and that in some
ases dysplastic changes may regress to non-dysplastic tissue.
oreover, high-grade dysplasia may persist for years before
rogressing to invasion. For this reason dysplasia appears
o be a limited marker for risk of cancer. However, no bet-
er biomarker is yet available, and high-grade dysplasia will
emain a mainstay of risk assessment in BE for some time
ntil newer technologies allow better risk assessment. In this
iagnostic process the pathologist has a predominant role.
n fact, when three pathologists agree on a diagnosis of low-
rade dysplasia (LGD), an elevated risk of progression exists,
erhaps because dysplasia on which any three pathologists
an agree is close to being high-grade [35].
.  Endoscopic  surveillance  for  patients  with  Barrett’s
sophagus: a matter  of  debate
Surveillance refers to periodic testing to detect disease or
otential disease in a person at high risk for disease (Fig. 2).
or patients with BE, the aim is to detect esophageal adeno-
arcinoma or high-grade dysplasia so that an early therapeutic
ntervention can result in a better outcome for those undergo-
ng surveillance [36]. To date, patients with BE undergoing
urveillance receive an endoscopy every 3–5 years for Bar-
ett’s metaplasia without dysplasia, every year for low-grade
ysplasia, and every 3 months for high-grade dysplasia if no
nvasive treatment is offered [25,37].
Patients with BE usually undergo endoscopic surveillance
t regular intervals, for instance every 2–3 years if no addi-
ional abnormal findings are found. As a consequence a
atient could undergo as many as ten or more surveillance
ndoscopies during their life time. As stated above, the inci-
ence of EA is low and the surveillance endoscopies in BE
atients usually don’t detect cancer [38].
Even if all patients with BE experience an increased risk
f developing esophageal adenocarcinoma, there are some
atients for whom surveillance would be unacceptable or
nappropriate.
To assess a real benefit from surveillance it is necessary
o evaluate its impact on reduction in mortality, earlier can-
er detection, and cost-effectiveness balance. The main aim
f a BE surveillance program should be the reduction of the
ortality from esophageal adenocarcinoma [39]. Mortality
elated to esophageal cancer in patients with BE is about 5%.
ince most BE patients die of causes other than esophageal
denocarcinoma, it may not be appropriate to offer routine
urveillance for BE [40,41]. For example, in elderly patients
ith BE the surveillance is not really useful because of the
igher the risk of death from other conditions. One might
till derive support for a surveillance program if there were
vidence that early detection was associated with improved
A. Russo et al. / Critical Reviews in Oncology/Hematology 86 (2013) 278–289 281
Fig. 1. Steps in Barrett’s carcinogenesis. The expected number of cases for each step by histologically confirmed endoscopic evaluation are
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rature [22]. GERD, gastroesophageal reflux disease; LGD, low-gra
urvival. The 1-year and 5-year survival rates are higher in
atients who have disease in situ than in those who have
istant spread [42]. This suggests that a surveillance pro-
ram has the potential to improve survival. Surveillance leads
o detection of malignancy at an earlier stage and is a pre-
ictor of survival following surgery. Surveillance-detected
denocarcinomas were associated with lower-stage disease
nd improved survival compared with cancers that were not
etected by surveillance [43,44]. BE surveillance may allow
arlier detection of esophageal adenocarcinoma with conse-
uent improvement in prognosis.
Furthermore, even if surveillance benefits some patients,
he cost per patient may be such that it is not beneficial
rom a societal stand-point. As the incidence of esophageal
denocarcinoma is low, even in patients with BE, there is a
onsiderable cost associated with the identification of each
ase of adenocarcinoma. When a surveillance strategy is lim-
ted to older white males, smokers, and patients with more
xtensive BE or dysplasia, there is evidence that this leads
o detection of disease when it is less advanced, with the
ubsequent potential improvement in prognosis.
m
t
c
ig. 2. Algorithm of endoscopic surveillance in subjects with Barrett’s esophagus, a
uidelines. LGD, low-grade dysplasia; HGD, high-grade dysplasia. next are inserted below. These data are extrapolated from the lit-
plasia; HGD, high-grade dysplasia; EA, esophageal adenocarcinoma
To achieve the ideal treatment when high-grade dysplasia
s found, a proper knowledge of the patient’s characteris-
ics is needed. Even if esophagectomy still remains the gold
tandard treatment for BE with high-grade dysplasia, mini-
ally invasive endoscopic and ablative techniques have been
ecently adopted. The endoscopic procedures included in
vailable options could be grouped into two major categories:
ndoscopic ablation of Barrett’s mucosa that can be achieved
y thermal, photodynamic and/or radiofrequency energy, and
ndoscopic mucosal resection. Randomized controlled trials
re mandatory to confirm the effectiveness of these methods
n preventing cancer development [45].
. Biomarkers  to  predict  progression  to  esophageal
denocarcinomaUseful biomarkers in BE help to predict the onset of pre-
alignant or malignant progression. Such markers are likely
o distinguish a priori between people with low and high
ancer risks. Ideal tests would be minimally invasive and
s defined by the American Society for Gastrointestinal Endoscopy (ASGE)
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ost-effective. It is desirable that the use of a biomarker in
onjunction with other markers will allow improved sensi-
ivity and specificity [46]. When a predictive biomarker is
efined, it could be applied in selecting those patients with BE
ho could benefit from a more frequent endoscopic surveil-
ance. The goal is to assess those predictive factors that may
ontribute to a better and quicker identification of patients
ith high-risk BE, so that surveillance strategies could be
arried out.
Only 5% of patients who present with esophageal adeno-
arcinoma already have a diagnosis of Barrett’s metaplasia
47]. For this reason methods for the detection of early
sophageal cancer need to be less invasive than endoscopic
iopsies. However, to date the only way to stratify patients
ccording to the risk of neoplasia of the esophagus involves
istopathology, as until now only dysplasia has been strongly
elated with EA onset.
.1.  DNA  content  abnormalities
DNA content abnormalities occur in cancer development
nd are studied to improve our understanding of neoplastic
ransformation. Since normal cells contain 46 chromosomes
2N), we refer to aneuploidy as the state in which cells have
n abnormal number of chromosomes. Tetraploidy refers to
ells that have double the number of chromosomes compared
o normal cells (4N).
In BE, aneuploidy has been correlated with the progres-
ion to EA [48,49]. An increase in 4N (G2/tetraploid) cells
redicts progression to aneuploidy. Moreover, the develop-
ent of 4N abnormalities is correlated with inactivation of
he p53 gene.
Some authors have combined an approach using flow
ytometry and histology with endoscopic biopsy. They
emonstrated the role of aneuploidy and increased 4N-cell
opulations as biomarkers to identify those patients with BE
t low and high risk of developing EA. More than 6% of
ells with 4N ploidy were considered abnormal. The relative
isk of cancer for these patients compared to those below this
ut-off value was 7.5 (95% CI: 4–14). In addition, patients
ho had baseline aneuploidy had a relative risk of cancer of
 (95% CI: 2.7–9.4) compared to patients who did not have
aseline aneuploidy.
.2.  p53
p53 loss of heterozygosity (LOH) provides one of the most
romising biomarkers to predict progression of BE. Silenc-
ng of p53 can occur via LOH or gene mutation. LOH of
hromosome 17p (p53) significantly increased the risk of
rogression to cancer (relative risk of 16, 95% CI: 6.2–39).
elative risk is higher when this biomarker is combined
ith aneuploidy (RR = 38.7, 95% CI: 10.8–138.5) [50,51].
he detection of LOH is complex and requires the col-
ection of snap-frozen samples followed by extraction of
NA and an amplification step prior to polymerase chain
t
a
t
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eaction (PCR) analysis [52]. For this reason immunos-
aining for p53 was studied as an alternative method. The
resence of p53 mutations can often cause protein accumu-
ation, which allows for detection by immunohistochemistry.
owever, the efficacy of this as a biomarker is limited,
ecause staining for p53 does not always correlate with muta-
ions, e.g. when it results from deletion or truncation of p53
53,54].
.3.  Cell  cycle  markers
Cyclin A and D have been also implicated in BE
s biomarkers. The over-expression of Cyclin D (a
roto-oncogene protein) in BE results in inappropriate phos-
horylation and inactivation of p105-Rb. This phenomenon
ay be correlated with the predisposition to neoplastic
ransformation and cancer development. For this reason it
as considered for studies on using it as a biomarker for
he identification of those patients with BE at high risk
f developing EA [55]. In a case–control study it was
hown that histochemical positivity for cyclin D predicts
igher probability of developing EA (OR: 6.85, 95% CI:
.57–29.91) [56]. However, these results were not confirmed
n another larger population-based case–control study, where
mmunohistochemical detection of p53 was shown to be
 useful biomarker for malignant progression in BE [53].
n a case–control study, surface expression of cyclin A in
E samples has been shown to be correlated with degree
f dysplasia. Those patients whose biopsies express cyclin
 had a higher probability of progressing to EA (OR: 7.5,
5% CI: 1.8–30.7) [57]. Prospective studies are required to
etermine properly the usefulness of cyclins as predictive
iomarkers.
.4.  Epigenetic  changes
Epigenetic changes – including hypomethylation, hyper-
ethylation, and alteration of histone complexes – seem to be
mplicated in Barrett’s carcinogenesis. In particular, hyper-
ethylation of the promoter CpG island of tumor suppressor
enes such as CDKN2A (p16), APC, CDH1 (E-cadherin),
nd ESR1 (ER, estrogen receptor α) induces transcriptional
ilencing. Hypermethylation of these genes is usually found
n a large contiguous field, suggesting either a concerted
ethylation change associated with metaplasia or a clonal
xpansion of cells with abnormal hypermethylation [58,59].
n patients with non-dysplastic BE and low-grade dysplasia
ethylation of p16 (OR: 1.74, 95% CI: 1.33–2.20), RUNX3
OR: 1.80, 95% CI: 1.08–2.81) and HPP1 (OR: 1.77, 95%
I: 1.06–2.81) were observed as independent risk factors for
rogression to high-grade dysplasia and EA [60]. A methyla-
ion panel including eight genes could accurately determine
he risk of progression in patients with BE, as shown in
 retrospective study. The promoter methylation levels of
hose eight genes were quantified by methylation-specific
CR in patients who did not progress compared to those
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ho did progress to high-grade dysplasia or EA. ROC curves
f the eight-gene methylation panel reached a specificity of
0% [61]. Another study combined four epigenetic (normal-
zed methylation values for p16, HPP1, and RUNX3 and
ethylation index) and three clinical (patient’s gender, BE
egment length, pathological assessment) parameters to strat-
fy the risk of progression to high-grade dysplasia and EA.
rogression-free survivals differed significantly among the
hree risk groups (high, intermediate and low risk) [38]. The
echanisms by which a high methylation index contributes
o carcinogenesis has not yet been clarified. Some hypothe-
es have been proposed to explain this phenomenon: (1)
ethylator phenotype-positive tumors are usually hyperme-
hylated in the promoter regions of other genes, including
umor suppressor genes (such as APC, CDH1, TIMP3, and
thers); (2) a methylator phenotype induces inactivation of
he hMLH1 gene by promoter hypermethylation, which in BE
ay causes microsatellite instability in the coding regions of
he tumor suppressor genes; (3) a methylator phenotype may
e associated with chromatin remodeling; and (4) methylated
ytosines are hotspots for mutations, for example in the p53
ene.
These studies indicate that changes in DNA methylation
ccur early in Barrett’s carcinogenesis. For this reason epige-
etics could be useful as biomarkers to identify those patients
ho are likely to progress to dysplasia and EA. However,
hese techniques are far too technically demanding and time-
onsuming for routine utilization in the clinic [62,63].
.5.  CDX  genes
CDX1 and CDX2 are transcription factors with a role in
he development of intestinal phenotypes of gastrointestinal
ells. In fact the gastric mucosa usually does not express
hese proteins; its epithelium becomes metaplastic through
he genetic engineering of gastric cells to express their genes
64,65]. Cdx1 and Cdx2 mediate the expression of cell adhe-
ion proteins and subsequent maintenance of morphology and
olarity in intestinal cells [66].
GERD-related damage to tight junctions between squa-
ous cells is mediated by acid. As a consequence
ermeability increases with dilation of intercellular spaces.
ndifferentiated cells in the basal layer of the epithelium are
xposed to acid, bile salts and inflammatory mediators. By
his mechanism these cells express CDX genes, and possibly
lso by epigenetic changes. Increased expression of these
orphogenetic genes mediates the expression of homeotic
enes that direct the squamous-to-columnar cell metaplasia
haracteristic of Barrett’s esophagus. This hypothesis is sup-
ort by the demonstration of high levels of CDX1 and CDX2
n the intestinal-type cells of Barrett’s metaplasia [67,68]. For
his reason a role for the measurement of CDX expression
evels in esophageal squamous epithelium to predict devel-
pment of BE in patients with GERD has been proposed
4].
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. The  microRNAs:  a  new  way  to  understand
arcinogenesis
.1.  Deﬁnition  of  microRNAs  and  their  role  in  cancer
MicroRNAs (miRNAs) are small (21–24 nucleotides
ong), endogenous, non-coding RNAs. Their direct effect is
ost-transcriptional gene silencing. Target mRNAs are rec-
gnized by base complementarity [69]. MiRNA genes are
ncoded in introns or exons of a protein-encoding gene or
n the intergenic regions, and it has been estimated that they
egulate up to 30% of human genes [70]. MiRNAs function
s regulatory molecules in a wide variety of fundamental
ellular processes, such as proliferation, death, differentia-
ion, motility and invasiveness [71]. Aberrant expression of
iRNAs has been observed in a diversity of pathological
vents. Importantly, deregulation or genetic changes of miR-
As have been critically implicated in the pathogenesis of
ost human cancers [72].
MiRNA biogenesis in the human cell is a multistep com-
lex process that begins in the nucleus, where miRNA
enes are transcribed by RNA polymerase II into long pri-
ary miRNAs (pri-miRNAs). Pri-miRNAs are subsequently
leaved into smaller, stem-looped, hairpin-like miRNA
recursors (pre-miRNAs) of ∼70 nt in length by an RNase-
II-type enzyme Drosha. Pre-miRNAs are exported from
he nucleus into the cytoplasm by Exportin-5. In the cyto-
lasm, pre-miRNAs are then cleaved by Dicer ribonuclease.
 single RNA strand is transferred to an argonaute pro-
ein within the RNA-induced silencing complex (RISC). The
ature miRNA strand is preferentially incorporated into a
icroRNA-induced silencing complex (miRISC), while the
ther strand of miRNA is degraded by the RISC. The miRNA
trand guides the RISC to its mRNA target containing a com-
lementary sequence to the mature miRNA and subsequently
nduces the cleavage or silencing of the target mRNA [73].
Single miRNAs and specific miRNA expression profiles
ave been identified as tumor-related. MiRNAs can be cat-
gorized in two groups based on their functional relevance.
iRNAs with an oncogenic effect are defined as oncogenic
iRNAs (oncomiRs). Those having a role as tumor suppres-
ors are categorized as tumor-suppressive miRNAs (ts-miRs).
n normal cells, ts-miRs are highly expressed and down-
egulate the expression of oncogenic proteins, whereas in
umor cells ts-miRs are silenced, leading to up-regulation of
ncogenic proteins. Conversely, oncomiRs are up-regulated
n tumor cells, down-regulating the expression of tumor-
uppressive proteins.
.2.  Role  of  microRNA  expression  changes  in  Barrett’s
arcinogenesisSince a differential expression of miRNAs was observed
etween normal esophageal epithelium and cancer cells, a
ole for miRNAs in the identification of patients at risk of
sophageal adenocarcinoma development has been suggested
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If this last hypothesis can be demonstrated we could sup-84 A. Russo et al. / Critical Reviews in 
74]. Several publications have described miRNA expres-
ion in BE and esophageal adenocarcinoma. Some of these
tudies performed miRNA microarray and q-PCR analysis
f miRNA expression in squamous esophageal epithelia,
ormal gastric epithelia, BE with intestinal metaplasia, and
sophageal adenocarcinoma, with the aim of identifying
ew biomarkers for the different steps of Barrett’s carcino-
enesis [75,76]. The choice of including normal squamous
sophageal epithelium in evaluating the differential miRNA
xpression profiles in the different steps of Barrett’s carcino-
enesis is questionable. In fact, the squamous phenotype
f the esophageal epithelium has no correlation with EA,
ut it should only be compared with esophageal squamous-
ell cancer. To clarify this point studies are needed on the
ifferentiation switch of progenitor cells from squamous to
olumnar-lined phenotypes and the correlation of this switch
ith carcinogenesis.
MiRNAs with differential expression patterns included
iR-21, miR-143, miR-145, miR-194, miR-203, miR-205
nd miR-215. However, various studies have also been per-
ormed to clarify the molecular consequences of the aberrant
iRNA expression.
MiR-21 expression is up-regulated in BE and esophageal
denocarcinoma, compared with squamous esophageal
pithelia, as found in other solid tumors [77]. Elevated miR-
1 has been implicated in many cellular processes required
or neoplastic development and progression. Some authors
ave argued that the up-regulation of miR-21 in a metaplas-
ic columnar epithelium may provide a selective advantage
o cells for neoplastic development to esophageal adenocar-
inoma [78].
miR-194 is also up-regulated in BE and esophageal adeno-
arcinoma. Expression of miR-194 is regulated by HNF-1a,
 transcription factor induced in BE and esophageal adeno-
arcinoma. During intestinal epithelial cell differentiation,
iR-194 expression has been shown to be induced [79].
ince its expression level was found to be increased even
n metastatic pancreatic cell lines, we could hypothesize that
levated miR-194 levels could favor both intestinal metapla-
ia in BE and tumor metastatic phenotype [80].
miR-143, miR-145 and miR-215 are down-regulated in
sophageal adenocarcinoma. Similar results have been found
n colon, gastric and lung cancer [81–83]. Some studies
ave helped to explain the mechanisms by which miR-143, -
45, and -215 induce carcinogenesis. For example, miR-143
argets the KRAS oncogene, so that colorectal cancer cell
rowth is inhibited by suppression of the translation of KRAS
RNA transcripts [84]. Up-regulated miR-143 also seems to
ave a role in FAS-mediated apoptosis [85]. These findings
mply that loss of miR-143 expression in esophageal adeno-
arcinoma could result in lack of KRAS regulation, which
avors neoplastic development.Since both miR-143 and miR-145 expression are
orrelated with p53, their loss may alter the apop-
otic responses in the progression of BE to esophageal
denocarcinoma [86,87].
p
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miR-215 together with miR-192 regulate cell cycle events
hrough their ability to induce cell cycle arrest. For this
eason the loss of miR-215 expression causes a reduc-
ion in the ability of cells to regulate proliferation, with
he subsequent advantage to neoplastic clones [88]. On
he basis of these findings we may define miR-143, -145
nd -215 as tumor suppressors, with loss of expression
ontributing to the development of esophageal adenocarci-
oma.
Two miRNAs recently showed roles as biomarkers in
arrett’s carcinogenesis. miR-31 was found to be down-
egulated in both HGD and EA, probably as a consequence
f the transition from BE to HGD. miR-375 showed marked
own-regulation exclusively in EA and not in BE or HGD
esions. For this reason it could be considered a marker of pro-
ression to invasive carcinoma. miR-31 and miR-375 were
roposed respectively as early and late biomarkers of malig-
ant progression from Barrett’s esophagus [89].
MiR-200 family members were also found to be down-
egulated in BE-derived high-grade dysplastic cell lines
ompared to a cell line derived from benign Barrett’s epithe-
ium. These miRNAs target ZEB1 and ZEB2, E-cadherin
ranscriptional repressors. ZEB1 and ZEB2 expression was
ignificantly higher in esophageal adenocarcinoma compared
o Barrett’s esophagus epithelium from patients without can-
er or dysplasia [90] (Table 1).
.3.  Hypotheses  for  the  causes  of  changes  in  microRNA
xpression
The studies reported here show the possible mechanisms
y which the miRNA variations in BE could modify the risk
f developing esophageal adenocarcinoma. These hypothe-
es could be made from the findings of other studies which
id not consider esophageal carcinogenesis [91]. However,
o date very little is known about the possible mechanisms
hich induce miRNA variations in esophageal epithelium.
or this reason some hypotheses could be proposed to induce
urther researches in this field. We provide some possible
xplanations, which need verification by specific studies:
1) polymorphisms could modify the basal levels of specific
iRNAs which have a role in cancer susceptibility through
dvantage to neoplastic clones; (2) the genetic mutations of
iRNA genes as a consequence of DNA damage could influ-
nce miRNA gene transcription; (3) the altered expression
f some oncogenes and tumor suppressor genes in the var-
ous steps of the carcinogenetic process could modify the
ranscription of specific miRNA genes; or (4) microenviron-
ental factors could induce modifications in the pathway of
iRNA biosynthesis.ose that miRNAs could mediate in the connection between
he action of carcinogenetic factors and the development of
ancer clones bearing mutations in oncogenes or tumor sup-
ressor genes.
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Table 1
miRNAs with differential expression in Barrett’s esophagus (BE) and esophageal adenocarcinoma (EA). The known functions for each miRNA have been
reported.
Ref. BE EA Function
miR-21 [77,78] ↑ ↑ Implicated in many cellular processes required for neoplastic development and progression
miR-194 [79,80] ↑ ↑ Implicated in intestinal epithelial cell differentiation
miR-143 [84–87] – ↓ Suppression of translation of KRAS mRNA transcripts
A role in FAS-mediated apoptosis
Correlation with p53
miR-145 [82,83] – ↓ Correlation with p53
miR-215 [81,88] – ↓ Reduction in the ability of cells to regulate proliferation
miR-31 [89] ↓ ↓ Early biomarkers of malignant progression from Barrett’s esophagus
miR-375 [89] – ↓ Late biomarkers of malignant progression from Barrett’s esophagus
miR-200 family [90] – ↓ Target ZEB1 and ZEB2, E-cadherin transcriptional repressors
e corre
7
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cFig. 3. The steps of progression toward esophageal adenocarcinoma. Th
.  Conclusions
BE is a medical condition correlated with GERD, since
cid reflux seems able to induce columnar metaplasia in
he distal esophageal epithelium. Little is known about the
ellular and molecular mechanisms which correlate with
t
a
blation between molecular changes and miRNA expression are reported.
his phenotypic change. The incidence of EA appears to
e on the increase, and this epidemiological phenomenon
ould be related to deteriorating lifestyle in Western coun-
ries. Because we know that dysplasia and adenocarcinoma
rise in those patients with columnar metaplasia, BE has
een considered as a predisposing condition for cancer. For
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his reason subjects with this condition may benefit from
urveillance by endoscopy and consequent early diagnosis of
sophageal cancer. The practical experience shows that long-
erm surveillance yields just a few cancer diagnoses despite
he great economic cost and the discomfort for those patients
ho accept endoscopy. Some researchers are trying to find
olecular alterations which could help in the selection of
igh-risk subjects as candidates for intensive surveillance.
o far various alterations have been found which may allow
his goal to be reached. These include DNA content abnor-
alities, p53 loss of heterozygosity, cell cycle markers, and
pigenetic changes. Recently miRNAs have also been studied
o identify significant differences between normal esophageal
ucosa, metaplasia, dysplasia and adenocarcinoma (Fig. 3).
owever, the results of these studies are quite heterogeneous,
nd a specific pattern of miRNA expression related to high
ancer risk has not yet been found. These findings provide an
nsight into potential molecular mechanisms to explain the
evelopment of adenocarcinoma from Barrett’s metaplasia.
iRNAs which show significant variations in dysplasia and
denocarcinoma should have a role in regulation of prolifer-
tion, and their alteration confers an advantage on neoplastic
lonal expansion. To date it is not clear what leads to alter-
tion in levels of miRNA expression. For this reason the
uestion arises, analyzing the role of molecular changes in
arrett’s carcinogenesis, including genetic, epigenetic and
iRNA variations: which came first, the chicken or the egg?
his conundrum refers to the possibility that those molecular
lterations known to characterize the different steps of car-
inogenesis could be consequences of microenvironmental
xposure to carcinogenetic agents and predisposing factors
or neoplastic transformation and clonal selection at the same
ime. We suppose that the solution of this question could
larify the reason why adenocarcinoma arises in BE.
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